Status: Recruiting
A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.
Participants needed: 52
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: GEn1E LifesciencesUpdated: Jun 23, 2026Locations: 11
Eligibility criteria
Male or female subject between the ages of 18 and 85 years old, inclusive. [+3]
Subject, surrogate, or physician not committed, or eligible, to receive full sup... [+23]